Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries
Andreas Wicki, insider at Harmony Biosciences

Andreas Wicki Insider Information

Director of Harmony Biosciences
Successful healthcare entrepreneur and investor with over 25 years of experience in the pharmaceutical and biotechnology industries. MSc and PhD in chemistry and biochemistry from the University of Berne, Switzerland. Previously co-owner and CEO of ANAWA Holding AG and Clinserve AG, two Contract Research Organisations specialising in analytical services. Board member of Harmony Biosciences, Buchler, and Pacira Pharmaceuticals.

What is Andreas Wicki's net worth?

The estimated net worth of Andreas Wicki is at least $189.91 million as of August 4th, 2022. Dr. Wicki owns 3,620,124 shares of Harmony Biosciences stock worth more than $189,911,705 as of August 10th. This net worth approximation does not reflect any other assets that Dr. Wicki may own. Learn More about Andreas Wicki's net worth.

How do I contact Andreas Wicki?

The corporate mailing address for Dr. Wicki and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at [email protected] Learn More on Andreas Wicki's contact information.

Has Andreas Wicki been buying or selling shares of Harmony Biosciences?

During the last quarter, Andreas Wicki has sold $665,748.80 in shares of Harmony Biosciences stock. Most recently, Andreas Wicki sold 12,640 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $52.67, for a transaction totalling $665,748.80. Following the completion of the sale, the director now directly owns 3,620,124 shares of the company's stock, valued at $190,671,931.08. Learn More on Andreas Wicki's trading history.

Who are Harmony Biosciences' active insiders?

Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.

Are insiders buying or selling shares of Harmony Biosciences?

In the last year, insiders at the sold shares 45 times. They sold a total of 1,425,753 shares worth more than $68,256,381.55. The most recent insider tranaction occured on August, 8th when Director Jack Nielsen sold 75,000 shares worth more than $4,017,000.00. Insiders at Harmony Biosciences own 34.7 % of the company. Learn More about insider trades at Harmony Biosciences.

Information on this page was last updated on 8/8/2022.

Andreas Wicki Insider Trading History at Harmony Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2022Sell12,640$52.67$665,748.803,620,124View SEC Filing Icon  
3/11/2022Sell70,370$44.14$3,106,131.80View SEC Filing Icon  
3/9/2022Sell140,000$45.49$6,368,600.00View SEC Filing Icon  
3/3/2022Sell175,000$41.01$7,176,750.00View SEC Filing Icon  
3/1/2022Sell92,501$40.24$3,722,240.24View SEC Filing Icon  
12/10/2021Sell2,585$40.08$103,606.80View SEC Filing Icon  
12/8/2021Sell24,683$40.09$989,541.47View SEC Filing Icon  
11/17/2021Sell1,417$41.25$58,451.25View SEC Filing Icon  
11/15/2021Sell35,600$42.08$1,498,048.00View SEC Filing Icon  
See Full Table

Andreas Wicki Buying and Selling Activity at Harmony Biosciences

This chart shows Andreas Wicki's buying and selling at Harmony Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harmony Biosciences Company Overview

Harmony Biosciences logo
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $52.46
Low: $51.00
High: $52.85

50 Day Range

MA: $49.90
Low: $42.48
High: $55.45

2 Week Range

Now: $52.46
Low: $28.01
High: $57.13

Volume

17,923 shs

Average Volume

496,947 shs

Market Capitalization

$3.10 billion

P/E Ratio

55.22

Dividend Yield

N/A

Beta

0.33
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
See How To Can Benefit From New Copper Discoveries